Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

7.63USD
14 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$7.63
Open
$8.69
Day's High
$9.01
Day's Low
$7.55
Volume
533,605
Avg. Vol
219,138
52-wk High
$15.81
52-wk Low
$6.68

Latest Key Developments (Source: Significant Developments)

ISS Recommends Keryx Biopharma Stockholders Vote For Proposed Merger With Akebia Therapeutics
Thursday, 29 Nov 2018 07:00am EST 

Nov 29 (Reuters) - Akebia Therapeutics Inc ::ISS RECOMMENDS THAT KERYX BIOPHARMACEUTICALS STOCKHOLDERS VOTE “FOR” THE PROPOSED MERGER WITH AKEBIA THERAPEUTICS.KERYX BIOPHARMACEUTICALS INC - LARGEST STOCKHOLDER, BAUPOST GROUP, LLC, HAS ENTERED INTO A VOTING AGREEMENT IN SUPPORT OF TRANSACTION.  Full Article

Akebia Therapeutics And Keryx Biopharmaceuticals Announce Chairperson For Combined Company
Thursday, 15 Nov 2018 05:15pm EST 

Nov 15 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS AND KERYX BIOPHARMACEUTICALS ANNOUNCE CHAIRPERSON FOR COMBINED COMPANY.AKEBIA THERAPEUTICS INC - UPON COMPLETION OF MERGER, BOARD OF DIRECTORS WILL CONSIST OF TEN MEMBERS WITH ADAMS AS CHAIRPERSON..AKEBIA THERAPEUTICS INC - CURRENT AKEBIA BOARD MEMBER MAXINE GOWEN WILL CONTINUE TO SERVE AS A MEMBER OF BOARD.AKEBIA THERAPEUTICS - CO, KERYX SAYS ADRIAN ADAMS WILL SERVE AS CHAIRPERSON OF AKEBIA BOARD OF DIRECTORS, EFFECTIVE UPON PROPOSED MERGER COMPLETION.  Full Article

Akebia Therapeutics Sends Letter To Shareholders
Tuesday, 13 Nov 2018 04:05pm EST 

Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS SENDS LETTER TO SHAREHOLDERS.AKEBIA THERAPEUTICS - AKEBIA BOARD UNANIMOUSLY RECOMMENDS THAT AKEBIA SHAREHOLDERS VOTE "FOR" PROPOSALS RELATING TO PROPOSED MERGER WITH KERYX.  Full Article

Akebia Therapeutics Reports Q3 Loss Per Share Of $0.46
Thursday, 8 Nov 2018 04:30pm EST 

Nov 8 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.46.Q3 EARNINGS PER SHARE VIEW $-0.64 -- THOMSON REUTERS I/B/E/S.COLLABORATION REVENUE WAS $53.2 MILLION FOR Q3 OF 2018 COMPARED TO $41.3 MILLION.ENDED Q3 OF 2018 WITH CASH, CASH EQUIVALENTS AND AVAILABLE FOR SALE SECURITIES OF $390.1 MILLION.  Full Article

Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock
Friday, 23 Mar 2018 08:00am EDT 

March 23 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.50 MILLION COMMON SHARES PRICED AT $10.50PER SHARE.  Full Article

Akebia Therapeutics Announces Proposed Public Offering Of Common Stock
Thursday, 22 Mar 2018 04:26pm EDT 

March 22 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AKEBIA THERAPEUTICS INC - INTENDS TO OFFER AND SELL APPROXIMATELY $85 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.AKEBIA - ‍INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL DEVELOPMENT, OPTIMIZATION OF VADADUSTAT PROGRAM.  Full Article

Akebia Therapeutics Announces Q4 Earnings Per Share $0.25
Monday, 12 Mar 2018 04:03pm EDT 

March 12 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.25.Q4 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S.AKEBIA THERAPEUTICS - EXPECTS EXISTING CASH RESOURCES TO FUND CURRENT OPERATING PLAN INTO Q2 2019.QTRLY COLLABORATION REVENUE $87.3 MILLION VERSUS $1.5 MILLION.EXPECTS EXISTING CASH RESOURCES WITH OTHERS TO FUND ITS CURRENT OPERATING PLAN INTO Q2 OF 2019.  Full Article

Akebia Therapeutics Announces Positive Results From Study Of Vadadustat In Japanese
Thursday, 4 Jan 2018 07:00am EST 

Jan 4 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA ASSOCIATED WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE.DATA CONSISTENT WITH FINDINGS FROM PREVIOUS STUDIES​.‍PHASE 3 STUDY OF NON-DIALYSIS PATIENTS IN JAPAN ONGOING; PHASE 3 STUDIES OF DIALYSIS PATIENTS TO BEGIN IN 2018​.STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY ENDPOINT OBSERVED IN VADADUSTAT GROUP 150 MG (P = 0.0004) COMPARED TO PLACEBO​.STATISTICALLY SIGNIFICANT IMPROVEMENTS ALSO OBSERVED IN VADADUSTAT GROUPS 300 MG(P<0.0001), 600 MG(P< 0.0001),COMPARED TO PLACEBO​.SERIOUS ADVERSE EVENTS WERE CONSISTENT WITH PRIOR STUDIES.NO DEATHS WERE REPORTED.  Full Article

Akebia Therapeutics reports Q3 loss per share $0.49
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.49.Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Akebia Therapeutics Inc -cash, cash equivalents and available for sale securities $329.7 million at sept 30 versus $260.3 million as at dec 31, 2016​.  Full Article

Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Akebia Therapeutics Inc :Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients with non-dialysis-dependent chronic kidney disease.Says ‍phase 3 study in Japan expected to commence by year-end 2017​.Says co provides Mitsubishi Tanabe with option to access global phase 3 vadadustat data for payments of up to $25 million​.Says ‍results confirm findings from previous studies of vadadustat​.Akebia Therapeutics Inc says MTPC will be responsible for all costs associated with phase 3 vadadustat program in Japan.Akebia Therapeutics Inc says expects to submit a Japanese New Drug Application (JNDA) for vadadustat with an anticipated launch in 2020..  Full Article

Former Akebia employee gets three years in prison for insider trading

A former Akebia Therapeutics Inc employee was sentenced on Monday to three years in prison after being convicted of working with a friend at a rival drugmaker to engage in insider trading based on information they learned about drug studies, according to the office of Massachusetts U.S. Attorney Andrew Lelling.